TransCon PTH is designed to be the first parathyroid hormone replacement therapy, addressing an area of major unmet medical need
COPENHAGEN, Denmark I November 14, 2022 I Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon PTH (palopegteriparatide) in adult patients with hypoparathyroidism. TransCon PTH is an investigational prodrug designed to restore parathyroid hormone (PTH [1-34]) to physiological levels over 24 hours in adult patients with hypoparathyroidism. Hypoparathyroidism is a rare disease that affects an estimated 85,000-223,000 patients in Europe, causing significant health and economic impacts on individual patients, families, and society.
“With a growing body of data showing durable, meaningful clinical and quality of life responses in the majority of treated patients, we believe TransCon PTH could, if approved, become the first treatment to address the underlying cause of hypoparathyroidism,” said Birgitte Volck, M.D., Ph.D., Senior Vice President, Head of Clinical Development & Medical Affairs, Endocrinology Rare Diseases, at Ascendis Pharma. “Our MAA submission is an important step in advancing our goal to bring TransCon PTH, if approved, to the substantial patient population in Europe who seek a treatment to address the short-term symptoms and long-term complications of their disease and support a normal daily life.”
The MAA is based on data from the global Phase 3 PaTHway Trial and the Phase 2 PaTH Forward Trial of TransCon PTH in adult patients with hypoparathyroidism. In the open-label portion of the Phase 2 trial, which includes patients treated beyond two years, 57 out of 59 patients continue. And in the open-label portion of the Phase 3 trial, 77 out of 79 patients continue, both as of September 30, 2022. In these studies, TransCon PTH has been generally well tolerated, with no discontinuations related to study drug.
The Company’s New Drug Application for TransCon PTH for adult patients with hypoparathyroidism is under Priority Review by the U.S. Food and Drug Administration, with a PDUFA target action date of April 30, 2023. TransCon PTH has been granted orphan designation in the United States and European Union.
About Hypoparathyroidism 1, 2, 3, 4, 5, 6
Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH), resulting in low calcium and elevated phosphate levels in the blood. Hypoparathyroidism affects approximately 200,000 patients in the United States, Europe, and Japan, most of whom develop the condition following damage to or accidental removal of the parathyroid glands during thyroid surgery. Conventional therapy with calcium supplements and active vitamin D (also called calcitriol) does not effectively address the short-term symptoms, long-term complications, or quality-of-life impacts of hypoparathyroidism.
Short-term symptoms include weakness, severe muscle cramps (tetany), abnormal sensations such as tingling, burning and numbness (paresthesia), memory loss, impaired judgment, and headache. Patients often experience decreased quality of life, and, over the long term, this complex disorder can increase risk of major complications, such as calcium deposits in the brain, blood vessels, eye, and other soft tissues – including the kidneys, which can lead to impaired renal function.
Hypoparathyroidism remains among the few hormonal insufficiency states without a replacement therapy to restore the missing hormone at physiologic levels. Conventional therapy with high doses of calcium and active vitamin D does not fully control the disease or address its underlying cause and may contribute to risk of renal disease. Patients with hypoparathyroidism have an estimated 4- to 8-fold greater risk of renal disease compared to healthy populations. Hypoparathyroidism is also associated with a 2-fold increased risk of depression or bipolar disorder compared to healthy populations.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology to build a leading, fully integrated, global biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Heidelberg and Berlin, Germany; Palo Alto and Redwood City, California; and Princeton, New Jersey. Please visit www.ascendispharma.com to learn more.
SOURCE: Ascendis Pharma
Post Views: 95
TransCon PTH is designed to be the first parathyroid hormone replacement therapy, addressing an area of major unmet medical need
COPENHAGEN, Denmark I November 14, 2022 I Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon PTH (palopegteriparatide) in adult patients with hypoparathyroidism. TransCon PTH is an investigational prodrug designed to restore parathyroid hormone (PTH [1-34]) to physiological levels over 24 hours in adult patients with hypoparathyroidism. Hypoparathyroidism is a rare disease that affects an estimated 85,000-223,000 patients in Europe, causing significant health and economic impacts on individual patients, families, and society.
“With a growing body of data showing durable, meaningful clinical and quality of life responses in the majority of treated patients, we believe TransCon PTH could, if approved, become the first treatment to address the underlying cause of hypoparathyroidism,” said Birgitte Volck, M.D., Ph.D., Senior Vice President, Head of Clinical Development & Medical Affairs, Endocrinology Rare Diseases, at Ascendis Pharma. “Our MAA submission is an important step in advancing our goal to bring TransCon PTH, if approved, to the substantial patient population in Europe who seek a treatment to address the short-term symptoms and long-term complications of their disease and support a normal daily life.”
The MAA is based on data from the global Phase 3 PaTHway Trial and the Phase 2 PaTH Forward Trial of TransCon PTH in adult patients with hypoparathyroidism. In the open-label portion of the Phase 2 trial, which includes patients treated beyond two years, 57 out of 59 patients continue. And in the open-label portion of the Phase 3 trial, 77 out of 79 patients continue, both as of September 30, 2022. In these studies, TransCon PTH has been generally well tolerated, with no discontinuations related to study drug.
The Company’s New Drug Application for TransCon PTH for adult patients with hypoparathyroidism is under Priority Review by the U.S. Food and Drug Administration, with a PDUFA target action date of April 30, 2023. TransCon PTH has been granted orphan designation in the United States and European Union.
About Hypoparathyroidism 1, 2, 3, 4, 5, 6
Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH), resulting in low calcium and elevated phosphate levels in the blood. Hypoparathyroidism affects approximately 200,000 patients in the United States, Europe, and Japan, most of whom develop the condition following damage to or accidental removal of the parathyroid glands during thyroid surgery. Conventional therapy with calcium supplements and active vitamin D (also called calcitriol) does not effectively address the short-term symptoms, long-term complications, or quality-of-life impacts of hypoparathyroidism.
Short-term symptoms include weakness, severe muscle cramps (tetany), abnormal sensations such as tingling, burning and numbness (paresthesia), memory loss, impaired judgment, and headache. Patients often experience decreased quality of life, and, over the long term, this complex disorder can increase risk of major complications, such as calcium deposits in the brain, blood vessels, eye, and other soft tissues – including the kidneys, which can lead to impaired renal function.
Hypoparathyroidism remains among the few hormonal insufficiency states without a replacement therapy to restore the missing hormone at physiologic levels. Conventional therapy with high doses of calcium and active vitamin D does not fully control the disease or address its underlying cause and may contribute to risk of renal disease. Patients with hypoparathyroidism have an estimated 4- to 8-fold greater risk of renal disease compared to healthy populations. Hypoparathyroidism is also associated with a 2-fold increased risk of depression or bipolar disorder compared to healthy populations.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology to build a leading, fully integrated, global biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Heidelberg and Berlin, Germany; Palo Alto and Redwood City, California; and Princeton, New Jersey. Please visit www.ascendispharma.com to learn more.
SOURCE: Ascendis Pharma
Post Views: 95
